The Institute of Cancer Research

(IN BRIEF) The Institute of Cancer Research has led a study showing that chromosomal instability in circulating tumour cells can predict resistance to cabazitaxel in men with advanced prostate cancer. Using blood samples from more than 200 patients enrolled in … Read the full press release →

(IN BRIEF) Researchers at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust have developed AI software that automates the complex interpretation of whole-body diffusion-weighted MRI scans, which are increasingly used to evaluate advanced prostate cancer. The … Read the full press release →

(IN BRIEF) The Institute of Cancer Research, London, has announced the launch of the £42 million TRANSFORM trial, the UK’s largest prostate cancer screening study in more than 20 years. The first men have now been invited by their GPs … Read the full press release →

(IN BRIEF) Researchers at The Institute of Cancer Research, London, have achieved a breakthrough in the treatment of advanced sarcoma and melanoma through a novel combination of isolated limb perfusion (ILP) and oncolytic virus therapy. In the first clinical trial … Read the full press release →

(IN BRIEF) The Phase III RAMPART trial has demonstrated that combining the immunotherapy drugs durvalumab and tremelimumab after surgery significantly improves disease-free survival in patients with early-stage renal cell carcinoma (RCC). Led by the Medical Research Council Clinical Trials Unit … Read the full press release →

(IN BRIEF) Long-term data from the international monarchE trial has confirmed that patients with HR+ and HER2- node-positive high-risk early breast cancer achieve better survival outcomes when treated with the targeted therapy abemaciclib in combination with standard hormone therapy. Presented … Read the full press release →

(IN BRIEF) In recognition of World Statistics Day 2025, The Institute of Cancer Research (ICR), London, is spotlighting the essential role of statisticians in advancing cancer research through reliable, transparent, and responsible data analysis. The event, themed “Quality statistics and … Read the full press release →

(IN BRIEF) A new global analysis by The Institute of Cancer Research (ICR), London, has found that cancer incidence is rising in both younger and older adults, disputing the idea that the global increase is limited to those under 50. … Read the full press release →

(IN BRIEF) A new study led by researchers at The Institute of Cancer Research, London, has identified a promising new combination therapy for pancreatic cancer that could transform future treatment. The dual approach — combining boiling histotripsy and oncolytic reovirus … Read the full press release →

(IN BRIEF) The Institute of Cancer Research has renewed its Athena Swan Silver Award for 2025–2029, recognising continued progress in promoting gender equality and fostering an inclusive workplace. The award highlights key achievements such as improved recruitment and flexible working … Read the full press release →

(IN BRIEF) The Institute of Cancer Research and NEOsphere Biotechnologies have announced a new collaboration to accelerate the discovery of molecular glue degrader drugs, an innovative approach in targeted cancer therapy. The partnership will integrate ICR’s proprietary molecular glue library … Read the full press release →

(IN BRIEF) The Institute of Cancer Research, London, has uncovered a promising new treatment target for pancreatic cancer, identifying the protein SPP1 as a driver of tumour spread and poor survival. In studies using tumour samples, organoids, and animal models, … Read the full press release →

(IN BRIEF) Scientists at the Institute of Cancer Research, London, together with colleagues from TUD Dresden University of Technology, have discovered that oxidation of a single site in the protein p21 acts as a chemical switch determining whether cells keep … Read the full press release →

(IN BRIEF) The Institute of Cancer Research, London, has published two major studies demonstrating how pairing a cancer-killing reovirus with targeted therapies such as talazoparib and palbociclib can greatly strengthen immune activity and tumour destruction. By disrupting cancer cell defences … Read the full press release →

(IN BRIEF) Researchers at The Institute of Cancer Research and Queen Mary University have created EIRAs, a computational assay that predicts how bowel cancer cells evolve resistance to chemotherapy. By monitoring cell populations and applying evolutionary models, the tool differentiates … Read the full press release →

(IN BRIEF) The largest study to date on testicular germ cell tumours (TGCTs) has revealed a potential link between testicular cancer risk and rare genetic variants affecting cellular movement and structure. Conducted by The Institute of Cancer Research, London, the … Read the full press release →

(IN BRIEF) A landmark international study has provided robust evidence that elevated levels of prolactin, a hormone involved in breast development, increase the risk of breast cancer in post-menopausal women. Researchers from The Institute of Cancer Research in London, along … Read the full press release →

(IN BRIEF) A groundbreaking AI-powered research platform, POETIC-AI, has been unveiled by scientists from The Institute of Cancer Research, promising to accelerate cancer biomarker discovery. Demonstrated at The Alan Turing Institute’s fifth AI UK conference, the platform integrates diverse clinical … Read the full press release →

(IN BRIEF) Scientists at The Institute of Cancer Research in London have made significant strides in understanding why some cases of neuroblastoma—a pediatric cancer of nerve tissue—result in poorer outcomes. Their research indicates that mutations in the ATRX gene, which … Read the full press release →

(IN BRIEF) Researchers at the Institute of Cancer Research in London have identified genetic markers that predict a significant survival benefit from combining ipatasertib with abiraterone in treating metastatic castration-resistant prostate cancer. In the phase III IPATential150 trial, patients whose … Read the full press release →